UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract CT204: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT204-CT204

2014

Volltextzugriff (PDF)

Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT217-CT217

2014

Volltextzugriff (PDF)

Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4633-4633

2014

Volltextzugriff (PDF)

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2592-2592

2014

Volltextzugriff (PDF)

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Blood, 2015-12, Vol.126 (23), p.4172-4172

2015

Volltextzugriff (PDF)

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Blood, 2013-11, Vol.122 (21), p.5572-5572

2013

Volltextzugriff (PDF)

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Blood, 2013-11, Vol.122 (21), p.5575-5575

2013

Volltextzugriff (PDF)

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Blood, 2013-11, Vol.122 (21), p.5571-5571

2013

Volltextzugriff (PDF)

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Blood, 2013-11, Vol.122 (21), p.5573-5573

2013

Volltextzugriff (PDF)

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Blood, 2013-11, Vol.122 (21), p.5570-5570

2013

Volltextzugriff (PDF)

Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13584-e13584

2015

Volltextzugriff (PDF)

Entospletinib drug interaction profile and mass balance

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14097-e14097

2016

Volltextzugriff (PDF)

Abstract 32: Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.32-32

2013

Volltextzugriff (PDF)

Population pharmacokinetic modeling of idelalisib, a novel PI3K[delta] inhibitor, in healthy subjects and patients with hematologic malignancies

Cancer chemotherapy and pharmacology, 2016-01, Vol.77 (1), p.89

2016

Volltextzugriff (PDF)

Drug interaction profile of idelalisib and its major metabolite, GS-563117

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2593-2593

2014

Volltextzugriff (PDF)

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Blood, 2013-11, Vol.122 (21), p.5054-5054

2013

Volltextzugriff (PDF)

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Blood, 2013-11, Vol.122 (21), p.5574-5574

2013

Volltextzugriff (PDF)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Blood, 2013-11, Vol.122 (21), p.5239-5239

2013

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetics Of GS-5806 in Healthy Japanese and Caucasian Subjects

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

768Evaluation of the Pharmacokinetics Of GS-5806 in Healthy Japanese and Caucasian Subjects

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S223-S223

2015

Volltextzugriff (PDF)

Drug Interaction Profile of GS-5806

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

765Drug Interaction Profile of GS-5806

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S222-S222

2015

Volltextzugriff (PDF)

Analysis of GS-5806 Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected With Respiratory Syncytial Virus (RSV)

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

1189Analysis of GS-5806 Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected With Respiratory Syncytial Virus (RSV)

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S353-S353

2015

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Thyroid
(1)

Kollektion

EZB Electronic Journals Library
(26)
Publisher or Other Site
(17)
Journals@Ovid Full Text
(12)
IngentaConnect Journals
(3)
IngentaConnect Journals
(2)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1)
Springer Nature
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(9)
Open Forum Infectious Diseases
(6)
Cancer Research
(4)
Journal Of Clinical Oncology
(4)
Asaio Journal
(1)
Cancer Chemotherapy And Pharmacology
(1)
Critical Care Medicine
(1)
Journal Of The Endocrine Society
(1)
Meeting Abstracts
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract CT204: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects

Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies

Entospletinib drug interaction profile and mass balance

Abstract 32: Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor

Population pharmacokinetic modeling of idelalisib, a novel PI3K[delta] inhibitor, in healthy subjects and patients with hematologic malignancies

Drug interaction profile of idelalisib and its major metabolite, GS-563117

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Evaluation of the Pharmacokinetics Of GS-5806 in Healthy Japanese and Caucasian Subjects

768Evaluation of the Pharmacokinetics Of GS-5806 in Healthy Japanese and Caucasian Subjects

Drug Interaction Profile of GS-5806

765Drug Interaction Profile of GS-5806

Analysis of GS-5806 Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected With Respiratory Syncytial Virus (RSV)

1189Analysis of GS-5806 Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected With Respiratory Syncytial Virus (RSV)

Aktive Filter

Suchergebnisse filtern